Abstract Library

#4281 Automated (artificial intelligence) vs. manual evaluation of the somatostatin-receptor 2A and proliferation marker Ki-67 in neuroendocrine neoplasms: A pilot study

Introduction: Digital image analysis methods are currently being equipped with artificial intelligence (AI). Various AI applications are already in use to determine Ki-67. To date, there is no specialised AI application available to determine the somatostatin-receptor 2A (SSTR2A).

Conference:

Presenting Author:

Authors: Kaemmerer D, Lupp A, Klöppel G, Ayako I, Kasajima A,

Keywords: artificial intelligence, Ki-67, SSTR2A, usability, neuroendocrine neoplasm,

#3290 Intratumoral serotonin might decrease the efficacy of PRRT in ileal neuroendocrine tumors

Introduction: Partial remission can be achieved by peptide receptor radionuclide therapy (PRRT) in only roughly 20% of patients with midgut neuroendocrine tumor (NET). This low remission rate can be due to the radioprotective role of stored intracytoplasmic serotonin in NET cells. If blocked, e.g. by telotristatethyl, PRRT efficacy might be increased.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Prasad V

Authors: Prasad V, Klöppel G, Lupp A, Wirtz R, Kaemmerer D,

Keywords: Ileal NET, serotonin, radioprotector, PRRT, immunohistochemistry, TPH1,

#2898 Novel Preclinical Models of Small Bowel Neuroendocrine Tumors for Drug Screening

Introduction: The incidence of neuroendocrine tumors (NETs) from the small bowel (SBNETs) has increased markedly over the past several decades. Many patients with these tumors present with metastatic disease, and research into new treatment options for these tumors have been hindered by the limited number of patient-derived SBNET cell lines and in vivo models available for drug testing.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Ear P

Authors: Ear P, Tran C, Li G, Kaemmer C, Ellen A,

Keywords: SBNET, drug screening, spheroids, PDX models, precision medicine,

#2845 Primary Tumour Resection and PRRT of NEN Stage IV - Are There Differences in Grading?

Introduction: The resection of primary tumours (PT) in patients with stage IV NEN is still a matter of debate. The resection of tumours with a low proliferation index (G1/G2) is more accepted then the resection of high proliferative tumours (G3-NET / G3-NEC).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Kaemmerer D, Trwznik M, Hörsch D, Baum R, Hommann M,

Keywords: Surgery, Primary tumor, PRRT, Grading,

#1827 Primary Tumor Resection Results in Superior Overall Survival after Peptide Receptor Radionuclide Therapy in Advanced Neuroendocrine Neoplasms

Introduction: Peptide receptor radionuclide therapy (PRRT) is an highly effective therapeutic option to treat advanced neuroendocrine neoplasms (NEN). However, it is still unclear whether resection of primary tumors improves overall survival (OS) after PRRT.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Kaemmerer D

Authors: Kaemmerer D, Twrznik M, Hommann M, Hörsch D, Baum R,

Keywords: PRRT, surgery,